Page
%P
-
Article
A phase III randomized, double-blind, placebo-controlled trial of the denosumab biosimilar QL1206 in postmenopausal Chinese women with osteoporosis and high fracture risk
The current study evaluated the efficacy and safety of a denosumab biosimilar, QL1206 (60 mg), compared to placebo in postmenopausal Chinese women with osteoporosis and high fracture risk. At 31 study centers ...
-
Article
Open AccessANP32A dysregulation contributes to abnormal megakaryopoiesis in acute megakaryoblastic leukemia